TY - JOUR
T1 - Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate
AU - Miller, Keren
AU - Erez, Rotem
AU - Segal, Ehud
AU - Shabat, Doron
AU - Satchi-Fainaro, Ronit
PY - 2009/4/6
Y1 - 2009/4/6
N2 - A polymer therapeutic designed for combination anticancer and antiangiogenic therapy inhibited the proliferation of prostate carcinoma cells and the proliferation, migration, and tube-formation of endothelial cells. The nanoconjugate was formed from an N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer, the bisphosphonate alendronate (for bone targeting), and the chemotherapy agent paclitaxel (PTX), which is cleaved by cathepsin B (see scheme).
AB - A polymer therapeutic designed for combination anticancer and antiangiogenic therapy inhibited the proliferation of prostate carcinoma cells and the proliferation, migration, and tube-formation of endothelial cells. The nanoconjugate was formed from an N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer, the bisphosphonate alendronate (for bone targeting), and the chemotherapy agent paclitaxel (PTX), which is cleaved by cathepsin B (see scheme).
UR - http://www.scopus.com/inward/record.url?scp=70349784954&partnerID=8YFLogxK
U2 - 10.1002/anie.200805133
DO - 10.1002/anie.200805133
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 19294707
AN - SCOPUS:70349784954
VL - 48
SP - 2949
EP - 2954
JO - Angewandte Chemie - International Edition
JF - Angewandte Chemie - International Edition
SN - 1433-7851
IS - 16
ER -